payor coverage

OKP will pay for testing if standard first trimester screening indicates a risk higher than 1:1000 for trisomies 21, 18, or 13.

Aetna is the first major commercial insurer to cover Interpace's ThyGenX and brings the total number of covered lives for it to more than 100 million. 

The test differentiates benign thyroid nodules from cancerous ones.

The company has received similar coverage decisions from other payors in recent months.

The decision means that UnitedHealthcare's members will have access to Biodesix's test for advanced NSCLC as a covered benefit.

About 19 million ACPN members will now have access to Cancer Genetics' cancer diagnostic services through their insurers.

The noninvasive colorectal cancer screening test will now be available to more than one million people in Massachusetts and Rhode Island.

In an update medical policy, Anthem said it will cover the test every three years for certain patients for whom the test is considered medically necessary. 

The firm plans to offer 5,350,000 shares of its common stock at a price between $13 and $15 per share.